FDA grants Priority Review to Dupixent® for kids 6 months to 5 yearsFebruary 10th 2022
The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.
How much do teens know about sun health and are they protecting themselves?November 17th 2021
Skin cancer is on the rise. Knowing what teenagers and adolescents understand about protecting skin from the sun and how well they’re using that information can be important to changing that trend.
Available biologics for treating asthma and allergic skin diseaseOctober 11th 2021
In cases of poorly controlled disease, even with good medication adherence, it might make sense to turn to biologics. A presentation at the virtual 2021 American Academy of Pediatrics National Conference & Exhibition covered biologics available for treating asthma and allergic skin disease.
Pearls for treating dermatologic conditions in skin of colorOctober 9th 2021
Treating dermatologic conditions in skin of color requires cultural awareness and sensitivity, in addition to being aware of how presentation may differ. At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, a session offered clinical pearls.